CA-074: Selective Cathepsin B Inhibitor for Cancer and Neurotoxicity Research

Executive Summary: CA-074 is a nanomolar-potency, highly selective cathepsin B inhibitor that enables precise study of proteolytic, metastatic, and neurotoxic pathways (Liu et al. 2023). It features a Ki of 2–5 nM for cathepsin B, with >10,000-fold selectivity over cathepsins H and L. In preclinical models, CA-074 suppresses bone metastasis and reduces neurotoxicity without significant cytotoxicity at 10 mM (APExBIO). The compound shifts immune responses from Th-2 to Th-1 by modulating helper T cell activity. Chemical inhibition of cathepsin B by CA-074 protects cells from necroptosis, demonstrating the critical role of cathepsin B in regulated cell death (Liu et al. 2023).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein degradation, cellular homeostasis, and regulation of cell death. Dysregulation of cathepsin B activity has been implicated in cancer metastasis, neurodegeneration, and immune disorders (Liu et al. 2023). During necroptosis, cathepsin B is released into the cytosol following MLKL-mediated lysosomal membrane permeabilization (LMP), contributing to cell death by cleaving survival proteins. In cancer, overactive cathepsin B degrades extracellular matrix components, facilitating tumor invasion and metastasis. In the CNS, cathepsin B released by activated microglia promotes neurotoxic cascades. Selective inhibition of cathepsin B allows researchers to dissect these disease processes with high specificity (Precision Cathepsin B Inhibition).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small-molecule inhibitor with the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid and a molecular weight of 383.44 g/mol (product page). It binds the active site of cathepsin B, inhibiting its proteolytic activity with a Ki of 2–5 nM. The selectivity profile is robust: Ki values for cathepsins H and L are 40–200 µM, indicating >10,000-fold selectivity. Mechanistically, CA-074 blocks cathepsin B–mediated proteolytic cascades, interrupting pathways essential for tumor metastasis, immune regulation, and neuronal injury. In models of necroptosis, CA-074 prevents cathepsin B–induced cleavage of survival proteins, reducing cell death after lysosomal disruption (Liu et al. 2023).

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with a Ki of 2–5 nM; Ki for cathepsin H/L is 40–200 µM, demonstrating high selectivity (APExBIO).
• Chemical inhibition of cathepsin B by CA-074 protects cells from necroptosis in human colon cancer HT-29 cells (DOI).
• Intraperitoneal injection of CA-074 (50 mg/kg) reduces bone metastasis in a 4T1.2 breast cancer mouse model without affecting primary tumor size (internal link).
• CA-074 reduces neurotoxicity by suppressing Abeta42-activated microglial cathepsin B activity (internal link).
• Compound shows negligible cytotoxicity at 10 mM in cell culture (APExBIO).
• Shifts helper T cell activity from Th-2 to Th-1, reducing IgE and IgG1 levels, indicating immune response modulation (internal link).

Applications, Limits & Misconceptions

CA-074 is widely used in cancer metastasis, neurotoxicity, and immune modulation studies. Its high selectivity allows for the study of cathepsin B–specific pathways with minimal off-target effects. In metastatic cancer models, CA-074 enables researchers to dissect the contribution of cathepsin B to tumor invasion and bone colonization. In neurodegenerative disease models, it allows for targeted inhibition of microglia-mediated neurotoxicity. Immune response studies leverage CA-074’s ability to shift T helper cell polarization. This article extends previous overviews (Precision Cathepsin B Inhibition) by integrating the latest MLKL-necroptosis mechanistic findings and providing implementation parameters for translational workflows.

Common Pitfalls or Misconceptions

• CA-074 does not significantly inhibit other cysteine cathepsins (e.g., H, L) at concentrations used for cathepsin B inhibition.
• It does not prevent necroptosis if cell death is independent of cathepsin B activity (Liu et al. 2023).
• Solubility in water is limited (max ~5.91 mg/mL with ultrasonication); improper dissolution may reduce efficacy (APExBIO).
• Prolonged storage of solutions leads to loss of potency; short-term use is recommended.
• Does not affect non-lysosomal protease pathways.

Workflow Integration & Parameters

CA-074 is supplied as a lyophilized powder. For in vitro use, dissolve in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water (>5.91 mg/mL with ultrasonic assistance). For cell culture, a final concentration up to 10 mM shows negligible cytotoxicity. For in vivo studies, a typical dose is 50 mg/kg administered via intraperitoneal injection in mice. Storage is recommended at −20°C; solutions should be freshly prepared or used within a short time frame. Refer to the CA-074, Cathepsin B inhibitor product page for details. For troubleshooting and advanced protocols, consult CA-074: Advancing Cathepsin B Inhibition in Necroptosis, which provides complementary guidance for optimizing necroptosis and metastasis studies.

Conclusion & Outlook

CA-074, provided by APExBIO, is a benchmark tool for dissecting cathepsin B–mediated pathways in cancer, neurotoxicity, and immune regulation. Its high selectivity and potency make it suitable for both in vitro and in vivo studies. Ongoing research continues to uncover new roles for cathepsin B in regulated cell death and disease, positioning CA-074 as a critical reagent for future mechanistic discoveries and drug development efforts. By integrating CA-074 into experimental workflows, researchers can precisely modulate cathepsin B activity and clarify its roles in pathological processes.